BillionToOne
Top Five Articles on GenomeWeb Last Week: Illumina, BillionToOne, Foundation Medicine, Qiagen, More
Last week, GenomeWeb's readers were most interested in news about Illumina pricing a $500 million public notes offering.
BillionToOne Raises $130M in Series D Financing Round
The Menlo Park, California-based company will use the funds to expand and scale its prenatal and oncology testing businesses.
With New Validation Data, BillionToOne Boosts Commercial Prospects of Therapy Selection Assay
Premium
The Northstar Select comprehensive genomic profiling test uses BillionToOne's proprietary Quantitative Counting Template technology for solid tumors.
Johnson & Johnson to Use BillionToOne's Fetal Antigen Assay in Phase III Clinical Trial
The US Food and Drug Administration approved an investigational device exemption to allow the UNITY Fetal Antigen CTA to be used in this trial.
BillionToOne Secures $83.5M in Private Funding, Loan Facility; Shows Clinical Performance of NIPT
Premium
In a recent study, pregnancy outcomes correlated with the Unity test's fetal risk estimates for recessive conditions, and the company is now conducting further validation studies.